
Zhitong Financial App News, Sihuan Pharmaceutical (00460) announced that patients with advanced breast cancer (HER2-) (HR2-) (HR+/HER2-) advanced breast cancer patients independently developed by Xuanzhu Biotechnology Co., Ltd. (Xuanzhu Biology, stock code: 02575.HK), a non-wholly-owned subsidiary of the group, combined with aromatase inhibitors (AI), are used in first-line treatment of positive hormone receptors (HR+) and human epidermal growth factor receptor 2 negative (HER2-) (HR+/HER2-). Industrial Injury Insurance Drug Catalogue (2026) )” (2026 National Basic Medical Insurance Drug Catalogue). The 2026 national basic medical insurance drug catalogue will be officially implemented on January 1, 2027. As of the date of this announcement, all three indications approved by piroxil in mainland China have been included in the national basic medical insurance drug catalogue.
As new indications for first-line treatment of HR+/HER2- advanced breast cancer are included in the 2026 national basic medical insurance drug catalogue, pirocilil tablets will achieve full medical insurance reimbursement coverage for HR+/HER2- advanced breast cancer first-line, second-line and later-line treatment scenarios. This move is expected to help reduce the financial burden of drug use on relevant patients and increase the accessibility of this innovative drug.
The board of directors believes that this inclusion will further expand the potential beneficiaries of pirosilil tablets, help accelerate their admission to hospitals and clinical application, thereby promoting the commercialization process of piroxilil tablets, and further consolidating the competitive advantage of Xuanzhu Biotech and the Group in the field of HR+/HER2- advanced breast cancer treatment.